HSP90AA1 and cancer: The antitumor effects of bortezomib (a proteasome inhibitor) elevated the expression of HSP60 and HSP90 on cancer cell surfaces and promoted phagocytosis by dendritic cells (DCs) in a murine model of ovarian cancer [122].